# Development of 11C-PABA as a bacteria-specific imaging agent for spinal infections

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2020 · $719,894

## Abstract

This proposal addresses a major challenge that radiologists and other physicians encounter frequently, namely
distinguishing active infection from other processes in the human body. Existing clinical techniques generally
target the host immune response, for example 111In SPECT white blood cell scanning or 18F-FDG PET.
Although these modalities can sometimes be useful, they lack the specificity required to distinguish living
bacteria from sterile inflammation, cancer, and other highly metabolic tissues. The central hypothesis of this
proposal is that imaging bacteria-specific metabolic pathways will afford a highly accurate method to
detect bacterial infections in vivo. We have identified 11C-PABA as a radiotracer with (1) a simple, high-
yield radio-synthesis (2) good in vivo stability (3) appropriate mimicry of the endogenous substrate (4) rapid
(minutes) rate of incorporation into both Gram-negative and Gram-positive bacteria, including clinical strains
and multi-drug resistant organisms and (5) low uptake in background tissues.
We propose a multi-PI and interdisciplinary collaboration across two institutions (University of California, San
Francisco – UCSF and Johns Hopkins) to validate 11C-PABA PET as a bacteria-specific imaging tool for spinal
infections and study it for the first time in human patients. We will investigate the sensitivity of 11C-PABA for
several relevant microorganisms, and compare its specificity to that of 18F-FDG and 68Ga-citrate in mouse
models (Specific Aim 1). We will then study 11C-PABA in compelling preclinical infection models, assessing in
vivo Gram-staining via a dual-tracer approach, rapid imaging readouts for antibiotic efficacy and evaluating
tracer performance in rat models of vertebral osteomyelitis-discitis (Specific Aim 2). In Specific Aim 3, we
will translate 11C-PABA under the Radioactive Drug Research Committee (RDRC) program and study its
performance in patients suffering from spinal infection.
Any imaging method that could confirm presence of infection as well as guide antibiotic therapy would be
profoundly helpful in clinical practice, sparing patients exposure to inappropriate broad spectrum antibiotics,
invasive tissue sampling and reducing the risks of antibiotic resistance. Finally, while the focus of this
application is on spinal infections, a clinically translatable bacteria-specific PET tracer would revolutionize the
workup and management of a large variety of clinically relevant bacterial infections.

## Key facts

- **NIH application ID:** 9859397
- **Project number:** 5R01EB025985-03
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** Sanjay K Jain
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $719,894
- **Award type:** 5
- **Project period:** 2018-05-01 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9859397

## Citation

> US National Institutes of Health, RePORTER application 9859397, Development of 11C-PABA as a bacteria-specific imaging agent for spinal infections (5R01EB025985-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9859397. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*